Key Events This Week
29 Jun: Week opens at Rs.2,407.45
30 Jun: Stock edges up 0.53% to Rs.2,420.15
1 Jul: Minor dip of 0.98% amid broader Sensex gains
2 Jul: Upgraded to Strong Buy; valuation shifts to very attractive
3 Jul: Strong rebound with 3.23% gain to close at Rs.2,476.10
29 June 2026: Steady Start Amid Stable Market
Lupin commenced the week at Rs.2,407.45, with a volume of 56,695 shares traded. The Sensex closed at 35,960.98, setting a neutral backdrop for the stock. No major news impacted the price on this day, and the stock held steady, reflecting investor patience ahead of anticipated corporate developments.
30 June 2026: Modest Gains Despite Sensex Dip
The stock advanced by 0.53% to Rs.2,420.15, even as the Sensex marginally declined by 0.01% to 35,958.71. Trading volume decreased to 36,595 shares. This relative strength suggested early positive sentiment, possibly in anticipation of the upcoming rating upgrade and valuation reassessment announced the following day.
1 July 2026: Minor Pullback on Broad Market Strength
On 1 July, Lupin’s price retreated by 0.98% to Rs.2,396.50, with volume at 31,634 shares. This dip occurred despite the Sensex rallying 0.45% to 36,119.01, indicating some profit-taking or short-term repositioning by investors ahead of the official upgrade announcements. The stock traded within a range of Rs.2,391.25 to Rs.2,440.40, maintaining proximity to its recent highs.
2 July 2026: Strong Upgrades Drive Positive Momentum
The pivotal day for Lupin was 2 July, when MarketsMOJO upgraded the stock’s mojo grade from Buy to Strong Buy, citing robust valuation and financial performance. The valuation grade shifted from attractive to very attractive, supported by a price-to-earnings ratio of 19.01, a low PEG ratio of 0.25, and an EV/EBITDA of 12.13, all signalling undervaluation relative to peers.
Financial metrics reinforced this upgrade, with net sales reaching ₹7,474.66 crores in Q4 FY25-26 and profit after tax surging 24.41% year-on-year to ₹1,560.39 crores. Lupin’s return on capital employed (ROCE) stood at an impressive 37.51%, and return on equity (ROE) at 25.68%, highlighting operational efficiency and strong shareholder returns. Institutional investors hold 47.03% of shares, reflecting confidence in the company’s fundamentals.
Despite a slight intraday decline of 0.98% to close at Rs.2,398.70, the stock’s technical indicators remained positive, supported by a 52-week trading range of Rs.1,838.65 to Rs.2,492.00 and a three-year total return of 165.48%, vastly outperforming the Sensex’s 18.86% over the same period.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
3 July 2026: Rebound to Weekly High on Positive Sentiment
Following the upgrades, Lupin rebounded strongly on 3 July, gaining 3.23% to close at Rs.2,476.10, the highest price of the week. The Sensex also advanced 0.15% to 36,431.45. Trading volume increased to 26,074 shares, reflecting renewed investor interest. This surge confirmed the market’s positive reception of Lupin’s improved valuation and mojo grade, reinforcing its status as a mid-cap outperformer within the Pharmaceuticals & Biotechnology sector.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-29 | Rs.2,407.45 | - | 35,960.98 | - |
| 2026-06-30 | Rs.2,420.15 | +0.53% | 35,958.71 | -0.01% |
| 2026-07-01 | Rs.2,396.50 | -0.98% | 36,119.01 | +0.45% |
| 2026-07-02 | Rs.2,398.70 | +0.09% | 36,376.02 | +0.71% |
| 2026-07-03 | Rs.2,476.10 | +3.23% | 36,431.45 | +0.15% |
Key Takeaways
Positive Signals: Lupin’s mojo grade upgrade to Strong Buy and valuation re-rating to very attractive reflect a comprehensive improvement in fundamentals, including a low PE ratio of 19.01, a PEG ratio of 0.25, and strong financial metrics such as a 24.41% PAT growth and a 37.51% ROCE. The stock’s outperformance relative to the Sensex (+2.85% vs +1.31%) and peers underscores its resilience and growth potential.
Cautionary Notes: Despite the overall positive momentum, the stock experienced a minor intraday dip on 1 July and 2 July, indicating some short-term volatility. The price-to-book value of 4.88, while reasonable within the sector, remains elevated compared to traditional benchmarks, suggesting investors should monitor valuation levels closely amid market fluctuations.
Lupin Ltd. caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Conclusion
Lupin Ltd’s performance during the week of 29 June to 3 July 2026 was marked by a notable outperformance relative to the Sensex, driven by significant upgrades in mojo grade and valuation status. The company’s robust financial results, attractive valuation multiples, and strong operational metrics underpin a positive market sentiment. While minor intraday volatility was observed, the overall trend remains favourable, positioning Lupin as a compelling mid-cap stock within the Pharmaceuticals & Biotechnology sector. Investors should continue to monitor the stock’s valuation and sector dynamics as it navigates evolving market conditions.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
